Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (12,569,390)	$ (4,840,463)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	652,209	107,948
Amortization of right of use assets	155,800	125,567
Depreciation	1,793	175
Forgiveness of PPP loan	(37,772)
Non-cash Interest on redeemable preferred stock	96,328
Long-term milestone payable due to Patagonia Pharmaceuticals LLC	1,750,000
Changes in assets and liabilities:
Other receivable		(253,892)
Prepaid research and development	(701,434)	(2,459)
Other current assets	6,864	1,367
Deposits		(13,000)
Accounts payable	(532,997)	990,803
Accrued expenses	558,411	(199,929)
Lease liability	(158,676)	(118,872)
Current milestone payable due to Patagonia Pharmaceuticals, LLC	2,250,000
Net cash used in operating activities	(8,528,864)	(4,202,755)
Cash flows from investing activities
Purchase of property and equipment	(5,947)	(16,903)
Net cash used in investing activities	(5,947)	(16,903)
Net decrease in cash	(8,534,811)	(4,219,658)
Cash, beginning of period	16,808,539	10,348,693
Cash, end of period	8,273,728	6,129,035
Non-cash investing and financing activities:
Long-term milestone payable to Patagonia Pharmaceuticals LLC	1,750,000
Accrued Series A preferred stock dividend		72,173
Cashless exercise of VARs	$ 60
Series A Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		2,060
Series B Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		$ 7,468